Quarterly report pursuant to Section 13 or 15(d)

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

v3.22.2.2
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE

  

          As of September 30, 2022     As of December 31, 2021  
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
              (unaudited)          
Asuragen acquisition:                        
Thyroid     9     $ 8,519     $ 8,519  
RedPath acquisition:                        
Pancreas test     7       16,141       16,141  
Barrett’s test     9       6,682       6,682  
                         
CLIA Lab     2.3       609       609  
                         
Total           $ 31,951     $ 31,951  
                         
Accumulated Amortization             (30,772 )     (29,819 )
                         
Net Carrying Value           $ 1,179     $ 2,132  
SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE

 

2022     2023     2024     2025     2026     Total  
                                             
$ 318     $ 861     $ -     $ -     $ -     $ 1,179  
SCHEDULE OF GOODWILL CARRYING VALUE

The following table displays a roll forward of the carrying amount of goodwill from December 31, 2021 to September 30, 2022:

  

    Carrying  
    Amount  
Balance as of December 31, 2021   $ 8,433  
Impairment from sale of Pharma Solutions Business     (8,433 )
Balance as of September 30, 2022   $ -